Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats

British Journal of Pharmacology

Volumn 138, Issue 7, 2003, Pages 1367-1375

  Cisternino, Salvatore ^a   Bourasset, Fanchon ^a   Archimbaud, Yves ^b   Sémiond, Dorothée ^b   Sanderink, Gérard ^b   Scherrmann, Jean Michel ^a  

^a HÔPITAL FERNAND WIDAL   (France)

^b SANOFI   (France)

Author keywords

Blood brain barrier; In situ brain perfusion; Multidrug resistance; P glycoprotein; Taxanes

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN P; TXD 258; TXD 258 CARBON C 14; UNCLASSIFIED DRUG;

ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN PERFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG INFUSION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TRANSPORT; FEMALE; FEMORAL VEIN; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; TRANSPORT KINETICS;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN; FEMALE; MICE; MICE, INBRED STRAINS; P-GLYCOPROTEIN; PACLITAXEL; PERFUSION; RATS;

EID: 0038415813     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705150     Document Type: Article

References (34)

1. ADACHI, Y., SUZUKI, H. & SUGIYAMA, Y. (2001). Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharma. Res., 18, 1660-1668.
2. AMBUDKAR, S.V., DEY, S., HRYCYNA, C.A., RAMACHANDRA, M., PASTAN, I. & GOTTESMAN, M.M. (1999). Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol., 39, 361-398.
3. BISSERY, M.C., BOUCHARD, H., RIOU, J.F., VRIGNAUD, C., COMBEAU, J., BOURZAT, J.D., COMMERCON, A. & LAVELLE, F. (2000). Preclinical evaluation of TXD258, a new taxoid. Proceedings of the 91st American Association for Cancer Research, San Francisco, CA, April 1 - 5, Vol. 41, p. 214.
4. BISSERY, M.C., NOHYNEK, G., SANDERINK, G.J. & LAVELLE, F. (1995). Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs, 6, 339-355, 363-368.
5. CLARKE, S.J. & RIVORY, L.P. (1999). Clinical pharmacokinetics of docetaxel. Clin. Pharmacokinet., 36, 99-114.
6. DAGENAIS, C., ROUSSELLE, C., POLLACK, G.M. & SCHERRMANN, J.M. (2000). Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein deficient mice. J. Cerebr. Blood Flow Metab., 20, 381-386.
7. DYKES, D.J., SARSAT, J.P. & BISSERY, M.C. (2000). Efficacy evaluation of TXD258, a taxoid compound against orthotopic and subcutaneous glioblastomas. Proceedings of the 91st American Association for Cancer Research, San Francisco, CA, April 1-5, Vol. 41, p. 301.
8. EISEMAN, J.L., EDDINGTON, N.D., LESLIE, J., MACAULEY, C., SENTZ, D.L., ZUHOWSKI, M., KUJAWA, J.M., YOUNG, D. & EGORIN, M.J. (1994). Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother. Pharmacol., 34, 465-471.
9. FERLINI, C., DISTEFANO, M., PIGNATELLI, F., LIN, S., RIVA, A., BOMBARDELLI, E., MANCUSO, S., OJIMA, I. & SCAMBIA, G. (2000). Antitumour activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitors. Br. J. Cancer, 83, 1762-1768.
10. GIANNI, L., KEARNS, C.M., GIANI, A., CAPRI, G., VIGANO, L., LACATELLI, A., BONADONNA, G. & EGORIN, M.J. (1995). Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol., 13, 180-190.
11. GOTTESMAN, M.M. & PASTAN, I. (1993). Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62, 385-427.
12. HEIMANS, J.J., VERMORKEN, J.B., WOLBERS, J.G., EELTINK, C.M., MEIJER, O.W., TAPHOORN, M.J. & BEIJNEN, J.H. (1994). Paclitaxel (Taxol) concentrations in brain tumor tissue. Ann. Oncol., 5, 951-953.
13. 3H]taxol in the Sprague -Dawley rat. Drug Metab. Dispos., 22, 254-258.
14. 3H]-paclitaxel in rats: a quantitative autoradiographic study. Cancer Chemother. Pharmacol., 37, 173-178.
15. LIN, S. & OJIMA, I. (2000). Recent strategies in the development of taxane anticancer drugs. Exp. Opin. Ther. Patents, 10, 869-889.
16. MARTIN, C., BERRIDGE, G., HIGGINS, C.F., MISTRY, P., CHARLTON, P. & CALLAGHAN, R. (2000). Communication between multiple drug binding sites on P-glycoprotein. Mol. Pharmacol., 58, 624-632.
17. ONETTO, N., CANETTA, R., WINOGRAD, B., CATANE, R., DOUGAN, M., GRECHKO, J., BURROUGHS, J. & ROZENCWEIG, M. (1993). Overview of Taxol safety. J. Natl. Cancer Inst. Monogr., 15, 131-139.
18. PARDRIDGE, W.M., CONNOR, J.D. & CRAWFORD, I.L. (1975). Permeability changes in the blood - brain barrier: causes and consequences. C.R.C. Crit. Rev. Toxicol., 2, 159-199.
19. ROMSICKI, Y. & SHAROM, F.J. (1999). The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry, 38, 6887-6896.
20. ROUSSELLE, C., CLAIR, P., LEFAUCONNIER, J.M., KACZOREK, M., SCHERRMANN, J.M. & TEMSAMANI, J. (2000). New advances in the transport of doxorubicin through the blood - brain barrier by a peptide vector-mediated strategy. Mol. Pharmacol., 57, 679-686.
21. SCHINKEL, A.H. (1999). P-glycoprotein, a gatekeeper in the blood - brain barrier. Adv. Drug. Deliv Rev., 36, 179-194.
22. SMITH, Q.R. (1996). Brain perfusion systems for studies of drug uptake and metabolism in the central nervous system. In: Models for Assessing Drug Absorption and Metabolism. ed. Borchardt, R.T., Smith, P.L. & Wilson, G. pp. 285-307. New York: Plenum Press.
23. SPARREBOOM, A., VAN TELLINGEN, O., NOOIJEN, W.J. & BEIJNEN, J.H. (1996). Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res., 56, 2112-2115.
24. STEIN, W.D. (1986). Transport and Diffusion Across Cell Membranes. Orlando, FL: Academic Press.
25. STEPHENS, R.H., O'NEILL, C.A., WARHURST, A., CARLSON, G.L., ROWLAND, M. & WARHURST, G. (2001). Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J. Pharmacol. Exp. Ther., 296, 584-591.
26. TAKASATO, Y., RAPOPORT, S.I. & SMITH, Q.R. (1984). An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am. J. Physiol., 247, H484-H493.
27. TRIGUERO, D., BUCIAK, J. & PARDRIDGE, W.M. (1990). Comparison of in vitro and in vivo models of drug transcytosis through the blood - brain barrier. J. Pharmacol. Exp. Ther., 253, 884-891.
28. TSUJI, A. & TAMAI, I. (1997). Blood - brain barrier function of P-glycoprotein. Adv. Drug Del. Rev., 25, 287-298.
29. VAN TELLINGEN, O., BEIJNEN, J.H., VERWEIJ, J., SCHERRENBURG, E.J., NOOIJEN, W.J. & SPARREBOOM, A. (1999a). Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. Clin. Cancer Res., 5, 2918-2924.
30. VAN TELLINGEN, O., HUIZING, M.T., PANDAY, V.R., SCHELLENS, J.H., NOOIJEN, W.J. & BEIJNEN, J.H. (1999b). Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br. J. Cancer., 81, 330-335.
31. VAN ZUYLEN, L., VERWEIJ, J. & SPARREBOOM, A. (2001). Role of formulation vehicles in taxane pharmacology. Invest. New Drugs., 19, 125-141.
32. VERWEIJ, J., CLAVEL, M. & CHEVALIER, B. (1994). Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann. Oncol., 5, 495-505.
33. VRIGNAUD, P., LEJEUNE, P., CHAPLIN, D., LAVELLE, F. & BISSERY, M.C. (2000). In vivo efficacy of TXD258, a new taxoid, against human tumor xenografts. Proceedings of the 91st American Association for Cancer Research, San Francisco, CA, April 1-5, Vol. 41, p. 214.
34. YAMAZAKI, M., NEWAY, W.E., OHE, T., CHEN, I., ROWE, J.F., HOCHMAN, J.H., CHIBA, M. & LIN, J.H. (2001). In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results. J. Pharmacol. Exp. Ther., 296, 723-735.